<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">JBM</journal-id><journal-title-group><journal-title>Journal of Biosciences and Medicines</journal-title></journal-title-group><issn pub-type="epub">2327-5081</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/jbm.2017.56004</article-id><article-id pub-id-type="publisher-id">JBM-77224</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biomedical&amp;Life Sciences</subject></subj-group></article-categories><title-group><article-title>
 
 
  Cutaneous Vasculitis with Renal Impairment in Octogenarian
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Thiago</surname><given-names>Sande Miguel</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Bruna</surname><given-names>Sande Miguel</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Vinicius</surname><given-names>Sande Miguel</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Jair</surname><given-names>Baptista Miguel</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Sebastião</surname><given-names>Celio Horta Coelho Filho</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Nayrton</surname><given-names>Kalys Cruz dos Anjos</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Lívia</surname><given-names>Cristina de Melo Pino</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Paola</surname><given-names>Stephanie Azevedo de Sá</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Vitor</surname><given-names>Araújo Goulart</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Daniel</surname><given-names>Almeida da Costa</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>The Medical School at the Center of Higher Education of Valen&amp;amp;ccedil;a, Valen&amp;amp;ccedil;a, Brazil</addr-line></aff><aff id="aff3"><addr-line>The Medical School at the Center of Higher Education of Valenca, Valenca, Brazil</addr-line></aff><aff id="aff2"><addr-line>Unigranrio Medical School, Rio de Janeiro, Brazil</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>acosttta@icloud.com(DADC)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>27</day><month>06</month><year>2017</year></pub-date><volume>05</volume><issue>06</issue><fpage>37</fpage><lpage>45</lpage><history><date date-type="received"><day>May</day>	<month>10,</month>	<year>2017</year></date><date date-type="rev-recd"><day>Accepted:</day>	<month>June</month>	<year>24,</year>	</date><date date-type="accepted"><day>June</day>	<month>27,</month>	<year>2017</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Henoch-Sch
  &amp;ouml;nlein purpura is a vasculitis of small vessels, characterized by tissue deposition of IgA, affecting predominantly the skin, intestine, joints and kidneys. It mainly affects the pediatric age group, especially from 2 to 11 years old. Most often, it is preceded by episode of upper airway infection from days to weeks. The most common clinical manifestations are purpuric cutaneous lesions located in the lower limbs and buttocks, abdominal pain in colic, nausea, vomiting, diarrhea, in addition to arthralgia/arthritis, usually with spontaneous resolution. Renal impairment usually manifests with hematuria and proteinuria, and renal function may also be impaired. The case described refers to a female patient, 86 years old, with a previous history of infection of the upper airways, followed by purpura in the lower limbs and renal impairment: serum creatinine 3.1 mg/dL (N 0.5 - 1.2 mg/dL); glomerular filtration rate 15 ml/min (N &gt; 60 ml/min); urea 118 mg/dL (N &lt; 40 g/dL); proteinuria 4.497 mg/24h. The present report aims to draw attention to the occurrence of Henoch-Sch
  &amp;ouml;nlein purpura in an atypical age group, with significant renal impairment, improvement only with conservative treatment, thus avoiding the use of immunosuppressants and the risks of immunosuppression and toxicity related to such drugs.
 
</p></abstract><kwd-group><kwd>Purple Henoch-Sch&#246;nlein</kwd><kwd> Vasculitis</kwd><kwd> Renal</kwd><kwd> Elderly</kwd><kwd> Case Report</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Henoch-Sch&#246;nlein purpura (PHS), also known as anaphylactoid purpura, allergic purpura, or non-thrombocytopenic rheumatic purpura, is the most prevalent vasculitis in the pediatric age group [<xref ref-type="bibr" rid="scirp.77224-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.77224-ref2">2</xref>] . It is characterized by the involvement of small vessels, venules and arterioles [<xref ref-type="bibr" rid="scirp.77224-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.77224-ref4">4</xref>] .</p><p>First described in 1801 by William Heberden [<xref ref-type="bibr" rid="scirp.77224-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.77224-ref6">6</xref>] , it was originally referred to as Willan-Heberden’s disease. In 1837 Johann Lukas Sch&#246;nlein recognized the association between purpura and arthritis [<xref ref-type="bibr" rid="scirp.77224-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.77224-ref7">7</xref>] . Eduard Heinrich Henoch later reported a case that also included abdominal pain, bloody diarrhea, and renal involvement [<xref ref-type="bibr" rid="scirp.77224-ref5">5</xref>] .</p><p>Such pathology is characterized by skin lesions in 100% of cases [<xref ref-type="bibr" rid="scirp.77224-ref3">3</xref>] , with symmetrical localization mainly in the buttocks and lower limbs [<xref ref-type="bibr" rid="scirp.77224-ref2">2</xref>] , gastrointestinal symptoms of 35% to 85%, renal alterations of 44% to 47% and arthralgia in 60% to 84% [<xref ref-type="bibr" rid="scirp.77224-ref4">4</xref>] .</p><p>The overall incidence in children was estimated at 13.5 cases per 100,000 children. However, the true incidence is probably underestimated because cases are not often reported to public health agencies [<xref ref-type="bibr" rid="scirp.77224-ref6">6</xref>] [<xref ref-type="bibr" rid="scirp.77224-ref8">8</xref>] .</p><p>Although the cause is unknown, it usually follows upper respiratory tract infection in days or weeks in up to 50% of cases [<xref ref-type="bibr" rid="scirp.77224-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.77224-ref9">9</xref>] [<xref ref-type="bibr" rid="scirp.77224-ref10">10</xref>] [<xref ref-type="bibr" rid="scirp.77224-ref11">11</xref>] . It has been proposed that beta-hemolytic group A streptococcus can be involved as a triggering factor, as well as the use of medications and vaccines and contact with specific food allergens, such as dyes and preservatives [<xref ref-type="bibr" rid="scirp.77224-ref9">9</xref>] .</p><p>There is a seasonal predominance in spring and winter between children and in the summer among adults. It is especially common among children, being the most affected male sex [<xref ref-type="bibr" rid="scirp.77224-ref12">12</xref>] . The peak incidence occurs between the ages of 2 and 11 years old. It is more common among Hispanics and whites. PHS is the most common form of vasculitis in childhood, but there are cases described up to 89 years of age, although 50% of all cases occur before 5 years of age, presenting more severe renal manifestations in adulthood, especially with the elderly, which may impact their life expectancy [<xref ref-type="bibr" rid="scirp.77224-ref10">10</xref>] [<xref ref-type="bibr" rid="scirp.77224-ref13">13</xref>] [<xref ref-type="bibr" rid="scirp.77224-ref14">14</xref>] .</p><p>It is generally presented as a classic tetrarch of rash, abdominal pain, renal disease and polyarthralgia [<xref ref-type="bibr" rid="scirp.77224-ref6">6</xref>] [<xref ref-type="bibr" rid="scirp.77224-ref10">10</xref>] [<xref ref-type="bibr" rid="scirp.77224-ref14">14</xref>] . Cutaneous lesions represent extravasation of blood in the skin, and often occur in groups that may persist for 3 to 10 days [<xref ref-type="bibr" rid="scirp.77224-ref14">14</xref>] [<xref ref-type="bibr" rid="scirp.77224-ref15">15</xref>] . The abdominal pain is the colic type, frequently manifested within 8 days after the onset of rash, associated with episodes of nausea, vomiting and diarrhea, or constipation and the presence of blood and faeces [<xref ref-type="bibr" rid="scirp.77224-ref15">15</xref>] . Renal impairment is the major prognostic factor of PHS [<xref ref-type="bibr" rid="scirp.77224-ref16">16</xref>] . The most evident changes are transient hematuria and proteinuria, with shorter durations for 1 month [<xref ref-type="bibr" rid="scirp.77224-ref4">4</xref>] . The prognosis is usually favorable, but some patients with nephritis may progress to renal failure [<xref ref-type="bibr" rid="scirp.77224-ref2">2</xref>] , characterized by systemic arterial hypertension, impaired renal function and glomerulonephritis [<xref ref-type="bibr" rid="scirp.77224-ref17">17</xref>] . polyarthralgia usually affects associated knees and ankles with spontaneous resolution [<xref ref-type="bibr" rid="scirp.77224-ref18">18</xref>] [<xref ref-type="bibr" rid="scirp.77224-ref19">19</xref>] . Cutaneous, gastrointestinal, renal and articular involvement are common features of the pathology, whereas orchitis, pulmonary haemorrhage and vasculitis of the central nervous system (CNS) are rarely evidenced [<xref ref-type="bibr" rid="scirp.77224-ref2">2</xref>] .</p><p>The diagnosis and the better knowledge of the etiopathogeny of vasculitis have made considerable progress in recent years, but there are still many points to be clarified in this group of diseases, given their heterogeneity and difficult therapeutic decisions [<xref ref-type="bibr" rid="scirp.77224-ref4">4</xref>] [<xref ref-type="bibr" rid="scirp.77224-ref17">17</xref>] .</p><p>PHS is a systemic vasculitis characterized by the deposition of immunoglobulin A (IgA). In the histopathological examination, there is a cutaneous component with lesions consisting of subepidermal hemorrhages and necrotizing vasculitis of the small vessels of the dermis [<xref ref-type="bibr" rid="scirp.77224-ref19">19</xref>] . The deposition of IgA, a prominent feature of fluorescence microscopy [<xref ref-type="bibr" rid="scirp.77224-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.77224-ref20">20</xref>] , is present in these vessels.</p><p>Cutaneous biopsies in which the subcutaneous tissue is not represented are inadequate for the investigation of vasculitis affecting small vessels. The pathophysiology of cutaneous vasculitis may be due to five major mechanisms: hypersensitivity mechanisms; mediated by type 1 reaction of Gel and Coombs, with active participation of eosinophils; Type 2 reaction of Gel and Coombs (antibody-mediated cytotoxicity); Immunocomplex mediated disease; and direct affection of the vessel [<xref ref-type="bibr" rid="scirp.77224-ref19">19</xref>] .</p><p>The presence of palpable purpura with the other components of tetrad makes the diagnosis straightforward. However, it is necessary to rule out other systemic auto-immune diseases, such as other forms of vasculitis or juvenile rheumatoid arthritis. Few laboratory tests are useful for diagnosis. Often mild leukocytosis with a normal platelet count is found. Elevation of IgA in the blood occurs in half of the patients and the definitive diagnosis is confirmed by a sample biopsy of the skin or kidney that has IgA deposition [<xref ref-type="bibr" rid="scirp.77224-ref10">10</xref>] [<xref ref-type="bibr" rid="scirp.77224-ref12">12</xref>] . In 1990, the American College of Rheumatology developed criteria for the diagnosis of PHS (<xref ref-type="table" rid="table1">Table 1</xref>). The diagnosis is given when the patient presents at least 2 of the 4 criteria.</p><p>The acute and active phase of PHS has spontaneous resolution in 94% of children and 89% of adults [<xref ref-type="bibr" rid="scirp.77224-ref13">13</xref>] . The patient should be checked for rare but serious complications such as hemorrhagic involvement of the renal, pulmonary, gastrointestinal, genitourinary and system central nervous system or joints, which usually occur within four weeks of the initial presentation, but may occur up to the eighth week. Serious kidney complications require referral to a nephrologist.</p><p>Regarding treatment, joint pain and painful soft tissue edema usually respond to acetaminophen or non-steroidal anti-inflammatory drugs [<xref ref-type="bibr" rid="scirp.77224-ref18">18</xref>] , but oral prednisone, from 1 to 2 mg/kg per day, may be necessary to accelerate its resolution [<xref ref-type="bibr" rid="scirp.77224-ref19">19</xref>] . Anti-inflammatory agents should be avoided in patients with extensive renal involvement.</p><p>Specific treatment of renal leukemia should be considered only in patients with significant proteinuria and with decreased glomerular filtration rate during</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Criteria for classification of Henoch-Sch&#246;lein purpura</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Purple palpable</th><th align="center" valign="middle" >Elevated purpura, not related to thrombocytopenia</th></tr></thead><tr><td align="center" valign="middle" >Age of onset less than 20 years</td><td align="center" valign="middle" >Age of onset of symptoms less than 20 years</td></tr><tr><td align="center" valign="middle" >Abdominal angina</td><td align="center" valign="middle" >Diffuse abdominal pain that intensifies with meals or intestinal bleeding</td></tr><tr><td align="center" valign="middle" >Changes in cutaneous biopsy</td><td align="center" valign="middle" >Histology showing granulocytes in arterioles or venules</td></tr></tbody></table></table-wrap><p>the acute episode. In these situations, a renal biopsy should be performed to assess the severity of the histological lesions, particularly the degree of growth, which seems to be the best prognostic indicator [<xref ref-type="bibr" rid="scirp.77224-ref13">13</xref>] [<xref ref-type="bibr" rid="scirp.77224-ref19">19</xref>] . The therapy is based on corticosteroids in high doses, alone or combined with immunosuppressive agents such as azathioprine, cyclophosphamide, or cyclosporine, in addition to warfarin and dipyridamole; high dose of immunoglobulins; plasmapheresis and renal transplantation [<xref ref-type="bibr" rid="scirp.77224-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.77224-ref7">7</xref>] [<xref ref-type="bibr" rid="scirp.77224-ref19">19</xref>] .</p><p>The aim of this report was to aggregate knowledge and stimulate the discussion of differential diagnoses of vasculitis in the elderly with their systemic manifestations, including the rarest forms of vascular involvement in this age group. Thus, generating a broader view of these pathologies, so that they are treated in a timely and appropriate manner, avoiding possible sequels.</p></sec><sec id="s2"><title>2. Case Report</title><p>An 86 years old patient, female, white, seamstress, widow, native of Santo Ant&#244;nio de P&#225;dua-RJ, Brazil. She presented with comorbidities, hypertension for 36 years in irregular treatment with losartan 100 mg/day, amlodipine 5 mg/day, spironolactone 25 mg/day and furosemide 40 mg/day, and diabetes mellitus, 30 years ago using metformin 1500 mg/day and glibenclamide 10 mg/day and peripheral arterial disease for 10 years using cilostazol 100 mg/day. She denied other comorbidities, food or drug allergies, smoking or alcoholism and previous surgeries.</p><p>She sought emergency room in August 2012, due to a history of upper airway infection (IVAS), myalgia, holocranial headache, vomiting, abdominal pain, and diabetes for approximately one week. On admission, she was in a regular state of being hypoxic (+/4), acyanotic, anicteric, axillary temperature 37.2˚C, dehydrated (++/4), PA: 160/90mmHg, HR: 108 bpm, RF: 18 ipm, cardiac and pulmonary auscultation without alterations. During hospitalization, there was improvement of the above picture. In parallel to the picture, there were purulent, maculopapular, erythematous lesions in the lower limbs and buttocks, not pruritic or desquamative. The laboratory tests performed at the time are shown in <xref ref-type="table" rid="table2">Table 2</xref></p><p>After resolving the condition, she was discharged from the hospital with a referral to the nephrology department, due to the retention of nitrogenous slags and proteinuria, where was asked for kidney and urinary tract ultrasound, biopsy of skin and renal lesions, and the latter was not performed due to patient refusal. Ultrasonography demonstrated topical kidneys of normal size, preserved echogenicity, cortico-medullary relationship compatible with the age of the patient. Skin biopsy demonstrated small vessels containing fibrin, neutrophils, and sometimes necrosis of the wall. Around it, there was extravasation of red blood cells and some neutrophils. Vessels of the deep plexus and of medium caliber free of lesions.</p><p>After discussing with the patient and family members about the therapeutic possibilities involving the use of corticosteroids, immunosuppressants and</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Results of laboratory tests</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Laboratory tests</th><th align="center" valign="middle" >Results</th><th align="center" valign="middle" >Normal</th></tr></thead><tr><td align="center" valign="middle" >Leukometry</td><td align="center" valign="middle" >12,480/mm<sup>3</sup></td><td align="center" valign="middle" >5000 - 10,000/mm<sup>3</sup></td></tr><tr><td align="center" valign="middle" >C reactive protein</td><td align="center" valign="middle" >12 mg/L</td><td align="center" valign="middle" >&lt;6 mg/L</td></tr><tr><td align="center" valign="middle" >Lactic dehydrogenase</td><td align="center" valign="middle" >320 UI/L</td><td align="center" valign="middle" >135 - 214 UI/L</td></tr><tr><td align="center" valign="middle" >Erythrocyte sedimentation rate</td><td align="center" valign="middle" >60 mm/1h</td><td align="center" valign="middle" >≤10 mm/1h</td></tr><tr><td align="center" valign="middle" >Platelet count</td><td align="center" valign="middle" >250,000/mm<sup>3</sup></td><td align="center" valign="middle" >150,000 - 450,00/mm<sup>3</sup></td></tr><tr><td align="center" valign="middle" >Prothrombin activity</td><td align="center" valign="middle" >92%</td><td align="center" valign="middle" >70% - 100%</td></tr><tr><td align="center" valign="middle" >INR</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1 - 1.5</td></tr><tr><td align="center" valign="middle" >Alkaline phosphatase</td><td align="center" valign="middle" >40 UI/L</td><td align="center" valign="middle" >25 - 100 UI/L</td></tr><tr><td align="center" valign="middle" >TGO</td><td align="center" valign="middle" >26 UI/L</td><td align="center" valign="middle" >≤31 UI/L</td></tr><tr><td align="center" valign="middle" >TGP</td><td align="center" valign="middle" >28 UI/L</td><td align="center" valign="middle" >≤31 UI/L</td></tr><tr><td align="center" valign="middle" >GGT</td><td align="center" valign="middle" >33 UI/L</td><td align="center" valign="middle" >≤43 UI/L</td></tr><tr><td align="center" valign="middle" >Serum creatinine</td><td align="center" valign="middle" >3.1 mg/dL</td><td align="center" valign="middle" >0.5 - 1.2 mg/dL</td></tr><tr><td align="center" valign="middle" >Glomerular filtration rate</td><td align="center" valign="middle" >15 ml/min</td><td align="center" valign="middle" >&gt;60 ml/min</td></tr><tr><td align="center" valign="middle" >Urea</td><td align="center" valign="middle" >118 mg/dL</td><td align="center" valign="middle" >&lt;40 mg/dL</td></tr><tr><td align="center" valign="middle" >Proteinuria</td><td align="center" valign="middle" >4497 mg/24hours</td><td align="center" valign="middle" >&lt;150 mg/24hours</td></tr></tbody></table></table-wrap><p>measures of blood pressure control and proteinuria, we chose only to institute the treatment of the last two through the use of losartan 50 mg, 12/12h. After four months of treatment initiation, proteinuria was 690 mg/24h and serum creatinine 1.18 mg/dL. On November 2014, still using losartan in the dose described above, the patient presented Proteinuria 783 mg/24h and serum creatinine of 1.37 mg/dL.</p><p>Although, in spite of all the patient-directed clinical follow-up and support, the patient opted only for blood pressure control and undertook the most detailed clinical follow-up of the condition from November 2014.</p><p>The patient was previously and properly explained about the report of her pathological condition, being in agreement with the publication of the same and signing the Term of Free and Informed Consent.</p><p><xref ref-type="fig" rid="fig1">Figure 1</xref> shows the detail of the infiltrate of neutrophils around the vessel with extravasated red blood cells (HE, 400x original increase).</p></sec><sec id="s3"><title>3. Discussion</title><p>According to Roberts et al. [<xref ref-type="bibr" rid="scirp.77224-ref14">14</xref>] , PHS is more prevalent in childhood, in the age group between 02 and 11 years old, with half of the cases occurring before the age of 5 years. The frequency of this purpura is lower in adults, corresponding to 20% - 30% of the cases [<xref ref-type="bibr" rid="scirp.77224-ref21">21</xref>] , which there is less knowledge about this condition in this age group, and especially in the elderly. Therefore, we deem it relevant to report this case. In addition, it must be emphasized that adult age involvement has a worse prognosis.</p><p>According to Brandt et al. [<xref ref-type="bibr" rid="scirp.77224-ref22">22</xref>] , the purpura can be preceded, for a period va-</p><fig-group id="fig1"><label><xref ref-type="fig" rid="fig1">Figure 1</xref></label><caption><title> Detail of the infiltrate of neutrophils * around the vessel with extravasated red blood cells ** (HE, 400x original increase).</title></caption><fig id ="fig1_1"><label>(b)</label><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/4-2150398x2.png"/></fig><fig id ="fig1_2"><label></label><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/4-2150398x3.png"/></fig></fig-group><p>rying from one to three weeks, by IVAS or streptococcal infection, the latter being involved in about one third of the cases, as well as the use of drugs and vaccines and contact with allergens. In the case presented, the patient started with IVAS, myalgia, headache, vomiting, abdominal pain and adynamia one week before the appearance of purpuric skin lesions. The presence of dyspnea, abdominal pain and vomiting may be the initial symptoms of PHS in 40% of the cases, a compatible picture presented by the patient in the emergency room [<xref ref-type="bibr" rid="scirp.77224-ref23">23</xref>] .</p><p>Brandt et al. [<xref ref-type="bibr" rid="scirp.77224-ref22">22</xref>] , further states that rashes may precede typical cutaneous manifestations, characterized by symmetrical hemorrhagic petechiae or palpable purpura in the limbs and gluteal region, sparing the trunk in general. The lesions reported in the present case presented as maculopapular, erythematous, non- pruritic or scaly lesions, purpuric and located below the waist line.</p><p>The diagnosis of PHS according to the American College of Rheumatology necessitates the presence of 2 of 4 previously mentioned criteria [<xref ref-type="bibr" rid="scirp.77224-ref6">6</xref>] . In this case, the following criteria may be cited: alteration in the biopsy of skin consisting of small vessels containing fibrin, neutrophils and sometimes, necrosis of the wall. In the perivascular region, there is extravasation of red blood cells and some neutrophils, and palpable purpura of 250,000/mm<sup>3</sup> (N 150,000 - 450,000/mm<sup>3</sup>).</p><p>Renal impairment is apparently more prevalent in older children and adults, usually manifesting as hematuria with or without hematic cylinders, and in mild or even absent proteinuria [<xref ref-type="bibr" rid="scirp.77224-ref21">21</xref>] . Nephrotic syndrome, elevated creatinine and hypertension are present in the minority of patients. These findings are associated with increased risk of progressive renal disease and occur more frequently in adults [<xref ref-type="bibr" rid="scirp.77224-ref21">21</xref>] . The laboratory tests during the hospitalization are shown in <xref ref-type="table" rid="table3">Table 3</xref>.</p><p>Although the patient did not present a fever and the cutaneous lesions were restricted to the buttocks and lower limbs, it evolved with impaired renal func-</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Laboratory tests during hospitalization</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Laboratory tests</th><th align="center" valign="middle" >Results</th><th align="center" valign="middle" >Normal</th></tr></thead><tr><td align="center" valign="middle" >Serum creatinine</td><td align="center" valign="middle" >3.1 mg/dL</td><td align="center" valign="middle" >0.5 - 1.2 mg/dL</td></tr><tr><td align="center" valign="middle" >Glomerular filtration rate</td><td align="center" valign="middle" >15 ml/min</td><td align="center" valign="middle" >&gt;60 ml/min</td></tr><tr><td align="center" valign="middle" >Urea</td><td align="center" valign="middle" >118 mg/dL</td><td align="center" valign="middle" >&lt;40 mg/dL</td></tr><tr><td align="center" valign="middle" >Proteinuria</td><td align="center" valign="middle" >4497 mg/24h</td><td align="center" valign="middle" >&lt;150 mg/24h</td></tr><tr><td align="center" valign="middle" >VHS</td><td align="center" valign="middle" >60 mm/1h</td><td align="center" valign="middle" >≤10 mm/1h</td></tr></tbody></table></table-wrap><p>tion, with increased nitrogen slags, proteinuria and decreased renal function, evidenced by a decrease in glomerular filtration rate, requiring referral to the nephrology department.</p><p>The diagnosis of renal impairment is based on clinical presentation, with renal biopsy being reserved for cases of uncertain diagnosis or more severe renal impairment (proteinuria &gt; 1 g/24h or a decrease in renal function) [<xref ref-type="bibr" rid="scirp.77224-ref24">24</xref>] . From renal biopsy findings a percentage of growing glomeruli appears to be the most important prognostic indicator [<xref ref-type="bibr" rid="scirp.77224-ref24">24</xref>] . Corticosteroid and immunosuppressive therapy should be considered only in patients with significant proteinuria or decreased renal function [<xref ref-type="bibr" rid="scirp.77224-ref24">24</xref>] . For cases of milder renal involvement with only microscopic or gross macroscopic hematuria, discrete proteinuria should only be monitored for the observation of worsening of proteinuria or renal function and control of blood pressure [<xref ref-type="bibr" rid="scirp.77224-ref24">24</xref>] . Biopsy and the use of corticosteroids and immunosuppressants are avoided in these cases. However, the patient refused the renal biopsy and opted only for the control of the arterial pressure and of proteinuria with an angiotensin II receptor blocking drug. In view of this, although it was explained about the importance of adequate treatment and its clinical-labora- torial follow-up, it was not possible to obtain further details of the long-term follow-up of the pathology, since the continuation of the case was impossible for the patient.</p></sec><sec id="s4"><title>4. Conclusion</title><p>The low frequency and the scarce literature on PHS in the advanced age group emphasize the need to discuss the present case, the diagnosis of which should be remembered in elderly patients affected by cutaneous vasculitis with renal involvement. The good evolution of the case without the use of specific immunosuppressive drugs, after discussing, the patient and family, emphasizes the necessity of the shared decision making as an objective to avoid aggressive treatment, in a situation where the therapeutic index bordering could cause harm to the patient, besides its basic pathological picture.</p></sec><sec id="s5"><title>Acknowledgements</title><p>Thanks to the Center of Higher Education of Valen&#231;a of Dom Andr&#233; Arcoverde Foundation.</p></sec><sec id="s6"><title>Cite this paper</title><p>Miguel, T.S., Miguel, B.S., Miguel, V.S., Miguel, J.B., Filho, S.C.H.C., dos Anjos, N.K.C., Pino, L.C.M., de S&#225;, P.S.A., Goulart, V.A. and da Costa, D.A. (2017) Cutaneous Vasculitis with Renal Impairment in Octogenarian. Journal of Biosciences and Medicines, 5, 37-45. https://doi.org/10.4236/jbm.2017.56004</p></sec></body><back><ref-list><title>References</title><ref id="scirp.77224-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Bailey, M., et al. (1998) The Effects of Vasculitis on the Gastrointestinal Tract and Liver. Gastroenterology Clinics of North America, 27, 747-782.https://doi.org/10.1016/S0889-8553(05)70032-7</mixed-citation></ref><ref id="scirp.77224-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Kiss, M.H.B., et al. (1994) Clinical, Laboratory and Therapeutic Aspects of 46 Children with Henoch-Sch&amp;ouml;nlein Purpura. The Journal of Pediatrics, 70, 234-239.https://doi.org/10.2223/JPED.716</mixed-citation></ref><ref id="scirp.77224-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Fervenza, F.C. (2003) Henoch-Sch&amp;ouml;nlein Purpura Nephritis. International Journal of Dermatology, 42, 170-177. https://doi.org/10.1046/j.1365-4362.2003.01769.x</mixed-citation></ref><ref id="scirp.77224-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Kaku, Y., Nokara, K. and Honda, S. (1998) Renal Involvement in Henoch- Sch&amp;ouml;nleinpurpura: A Multivariate Analysis of Prognostic Factors. Kidney International, 53, 1755-1759. https://doi.org/10.1046/j.1523-1755.1998.00915.x</mixed-citation></ref><ref id="scirp.77224-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Ballinger, S. (2003) Henoch-Sch&amp;ouml;nlein Purple. Current Opinion in Rheumatology, 15, 591-594. https://doi.org/10.1097/00002281-200309000-00012</mixed-citation></ref><ref id="scirp.77224-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Mills, J.A., Michel, B.A., Bloch, D.A., et al. (1990) The American College of Rheumatology 1990 Criteria for the Classification of Henoch-Sch&amp;ouml;nlein Purpura. Arthritis &amp; Rheumatology, 33, 1114-1121. https://doi.org/10.1002/art.1780330809</mixed-citation></ref><ref id="scirp.77224-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Blanco, R., Martinez-Taboada, V.M., Rodriguez-Valverde, V., et al. (1997) Henoch-Sch&amp;ouml;nlein Purpura in Adulthood and Childhood: Two Different Expressions of the Same Syndrome. Arthritis &amp; Rheumatology, 40, 859-864.https://doi.org/10.1002/art.1780400513</mixed-citation></ref><ref id="scirp.77224-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Saulsbury, F.T. (2001) Henoch-Sch&amp;ouml;nlein Purple. Current Opinion in Rheumatology, 13, 35-40. https://doi.org/10.1097/00002281-200101000-00006</mixed-citation></ref><ref id="scirp.77224-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Ronkainen, J., et al. (2003) Outcome of Henoch-Sch&amp;ouml;nlein Nephritis with Nephrotic-Range Proteinuria. Clinical Nephrology, 60, 80-84.</mixed-citation></ref><ref id="scirp.77224-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Robson, W.L. and Leung, A.K. (1994) Henoch-Sch&amp;ouml;nlein Purple. Advances in Pediatrics, 41, 163-194.</mixed-citation></ref><ref id="scirp.77224-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Szer, I.S. (1994) Henoch-Sch&amp;ouml;nlein Purple. Current Opinion in Rheumatology, 6, 25-31. https://doi.org/10.1097/00002281-199401000-00005</mixed-citation></ref><ref id="scirp.77224-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Halling, S.F., Soderberg, M.P. and Berg, U.B. (2005) Henoch Sch&amp;ouml;nleinnephritis: Clinical Findings Related to Renal Function and Morphology. Pediatric Nephrology, 20, 46-51. https://doi.org/10.1007/s00467-004-1650-6</mixed-citation></ref><ref id="scirp.77224-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Gedalia, A. (2004) Henoch-Sch&amp;ouml;nlein Purpura. Current Opinion in Rheumatology, 6, 195-202. https://doi.org/10.1007/s11926-004-0068-2</mixed-citation></ref><ref id="scirp.77224-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Roberts, P.F., et al. (2007) Henoch-Sch&amp;ouml;nlein Purpura: A Review Article. Southern Medical Journal, 100, 821-824. https://doi.org/10.1097/SMJ.0b013e3180f62d0f</mixed-citation></ref><ref id="scirp.77224-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Leung, A.K. and Chan, K.W. (2001) Evaluating the Child with Purple. American Family Physician, 64, 419-429.</mixed-citation></ref><ref id="scirp.77224-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Shin, J.I., et al. (2006) Predictive Factors for Nephritis, Relapse, and Significant Proteinuria in Childhood Henoch-Sch&amp;ouml;nlein Purpura. Scandinavian Journal of Rheumatology, 35, 56-60. https://doi.org/10.1080/03009740510026841</mixed-citation></ref><ref id="scirp.77224-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Stewart, M., et al. (1988) Longterm Renal Prognosis of Henoch-Sch&amp;ouml;nlein Purpura in an Unselected Childhood Population. European Journal of Pediatrics, 147, 113-115. https://doi.org/10.1007/BF00442205</mixed-citation></ref><ref id="scirp.77224-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Giangiacomo, J. and Tsai, C.C. (2007) Dermaland Glomerular Deposition of IgA in Anaphylactoid Purpura. American Journal of Diseases of Children, 131, 981-983.</mixed-citation></ref><ref id="scirp.77224-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Rostoker, G. (2001) Sch&amp;ouml;nlein-Henoch Purpura in Children and Adults: Diagnosis, Pathophysiology and Management. BioDrugs, 15, 99-138.https://doi.org/10.2165/00063030-200115020-00004</mixed-citation></ref><ref id="scirp.77224-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Saulsbury, F.T. (2002) Epidemiology of Henoch-Sch&amp;ouml;nlein Purpura. Cleveland Clinic Journal of Medicine, 69, SII87-9. https://doi.org/10.3949/ccjm.69.suppl_2.sii87</mixed-citation></ref><ref id="scirp.77224-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Dedeoglu, F. and Kim, S. (2017) Sch&amp;ouml;nlein-Henoch Purpura (Immunoglobulin A Vasculitis): Clinical Manifestations and Diagnosis. https://www.uptodate.com/contents/henoch-schonlein-purpura-immunoglobulin-vasculitis-clinical-manifestations-and-diagnosis</mixed-citation></ref><ref id="scirp.77224-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Brandt, H.R.C., Arnone, M., Valente, N.Y.S., Criado, P.R. and Sotto, M.N. (2017) Vasculite cutanea de pequenos vasos: Etiologia, patogênese, classificacao e critérios diagnósticos—Parte I. Anais Brasileiros de Dermatologia, 82, 387-406. https://doi.org/10.1590/S0365-05962007000500002</mixed-citation></ref><ref id="scirp.77224-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Brandt, H.R.C., Arnone, M., Valente, N.Y.S., Criado, P.R. and Sotto, M.N. (2007)  Vasculite cutanea de pequenos vasos: Subtipos e tratamento—Parte II. Anais Brasileiros de Dermatologia, 82, 499-511. http://www.scielo.br/scielo.php?script=sci_arttext&amp;pid=S0365-05962007000600002&amp;lng=pt</mixed-citation></ref><ref id="scirp.77224-ref24"><label>24</label><mixed-citation publication-type="book" xlink:type="simple">Niaudet, P., Appel, G.B. and Hunder, G.G. (2017) Renal Manifestationsof Henoch-Scholein Purpura (IgAvasculitis). Basow, D., Ed., UptoDate, Waltham, MA. https://www.uptodate.com/contents/renal-manifestations-of-henoch-schonlein-purpura-iga-vasculitis</mixed-citation></ref></ref-list></back></article>